Kabayama Y, Kato Y, Tojo K, Shimatsu A, Ohta H, Imura H
Life Sci. 1985 Apr 1;36(13):1287-94. doi: 10.1016/0024-3205(85)90274-7.
Intracerebroventricular (icv) injection of DN1417 (0.3, 3 and 30 nmol/rat), a TRH analog, resulted in a dose-related increase in plasma glucose, epinephrine and norepinephrine levels in conscious male rats. The effects of DN1417 were more potent and longer-lasting than those of TRH on a molar basis. Intravenous injection of DN1417 (30 nmol/rat) did not change plasma glucose, epinephrine and norepinephrine levels. Pretreatment with hexamethonium (1.5 mg/100 g body wt, iv, 2 min before) inhibited plasma glucose, epinephrine and norepinephrine responses to DN1417 (3 nmol/rat, icv). DN1417 did not change plasma glucose, epinephrine and norepinephrine levels in rats after total adrenalectomy. In the animals pretreated with cysteamine (30 mg/100 g body wt, sc, 4 h before), basal plasma glucose, epinephrine and norepinephrine levels were raised, and exaggerated responses of plasma glucose, epinephrine and norepinephrine to DN1417 (3 nmol/rat, icv) were obtained. These results indicate that DN1417 has a potent and long-lasting effect in the central nervous system in stimulating the secretion of catecholamines through the autonomic nervous system, which is associated with an elevation of plasma glucose and that endogenous hypothalamic somatostatin may inhibit the action of DN1417.
向清醒雄性大鼠脑室内注射促甲状腺激素释放激素（TRH）类似物DN1417（0.3、3和30 nmol/大鼠），可导致血浆葡萄糖、肾上腺素和去甲肾上腺素水平呈剂量依赖性升高。按摩尔计算，DN1417的作用比TRH更强且更持久。静脉注射DN1417（30 nmol/大鼠）不会改变血浆葡萄糖、肾上腺素和去甲肾上腺素水平。六甲铵预处理（1.5 mg/100 g体重，静脉注射，提前2分钟）可抑制血浆葡萄糖、肾上腺素和去甲肾上腺素对DN1417（3 nmol/大鼠，脑室内注射）的反应。全肾上腺切除术后，DN1417不会改变大鼠的血浆葡萄糖、肾上腺素和去甲肾上腺素水平。在半胱胺预处理（30 mg/100 g体重，皮下注射，提前4小时）的动物中，基础血浆葡萄糖、肾上腺素和去甲肾上腺素水平升高，且对DN1417（3 nmol/大鼠，脑室内注射）的血浆葡萄糖、肾上腺素和去甲肾上腺素反应增强。这些结果表明，DN1417在中枢神经系统中具有强大且持久的作用，可通过自主神经系统刺激儿茶酚胺分泌，这与血浆葡萄糖升高有关，并且内源性下丘脑生长抑素可能会抑制DN1417的作用。
